AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25823600
Drug: No Oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Oral Immunotherapy (No OIT)
Trial: 25823737
Drug: Tumor-infiltrating T
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-infiltrating T cells selected for HPV E6 and E7 reactivity (HPV-TILs) infused after lymphocyte-depleting chemotherapy and followed by aldesleukin administration.
Trial: 25823737
Drug: HPV-TILs infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HPV-TILs infusion product
Trial: 25823737
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of HPV-reactive T cells in peripheral blood 1 month after treatment
Trial: 25823919
Drug: Buprenorphine-naloxone buccal
RxNorm normalized name: buprenorphine / naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone buccal film (BBN)
Trial: 25824215
Drug: Rifapentine 10
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 10 mg/kg twice daily for 14 days
Trial: 25824215
Drug: Rifapentine 20
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 20 mg/kg once daily for 14 days
Trial: 25824215
Drug: Rifapentine 15
RxNorm normalized name: rifapentine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine 15 mg/kg once daily with a high-fat breakfast
Trial: 25824215
Drug: Rifapentine divided
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine divided dosing (e.g., 1,500 mg/day)
Trial: 25824314
Drug: Rheolytic thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheolytic thrombectomy (RT) without lytic agent
Trial: 25824314
Drug: RT in
RxNorm normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RT in combination with CDT
Trial: 25824314
Drug: Rheolytic PCDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheolytic PCDT treatment
Trial: 25825476
Drug: Afatinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (20 mg/d) and trastuzumab (6 mg/kg/3 weeks) for 6 weeks, followed by paclitaxel (80 mg/m2/1 week), trastuzumab, and afatinib for 12 weeks, followed by epirubicin (90 mg/m2/3 weeks), cyclophosphamide (600 mg/m2/3 weeks), and trastuzumab for 12 weeks
Trial: 25825625
Drug: Community health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community health worker (CHW) administered stroke symptom questionnaire (QVSFS)
Trial: 25827820
Drug: MK-2206 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 (60 mg every other day)
Trial: 25827941
Drug: Dalteparin (subcutaneous)
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (subcutaneous) for 12 months
Trial: 25829395
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg kg(-1)
Trial: 25829804
Drug: Abcertin® administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abcertin® administered at the same dose as imiglucerase (30 to 55 U/kg every other week) for 24 weeks
Trial: 25832001
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN-α) treatment
Trial: 25833390
Drug: Bortezomib in
RxNorm normalized name: bortezomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib in combination with ifosfamide and vinorelbine (IVB)
Trial: 25834212
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 40 mg every other week for up to 12 weeks or 20 weeks
Trial: 25837499
Drug: Lenalidomide 15
RxNorm normalized name: lenalidomide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 15 mg daily
Trial: 25837499
Drug: Lenalidomide 20
RxNorm normalized name: lenalidomide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 20 mg daily
Trial: 25837499
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 intravenously (days 1, 8, and 15)
Trial: 25837499
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) as prophylactic anticoagulant
Trial: 25837499
Drug: Overall treatment-related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment-related adverse events (AEs)
Trial: 25837801
Drug: Early levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early levosimendan administration (perioperatively up to the first hour after ICU admission)
Trial: 25837801
Drug: Late levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late levosimendan administration (later than the first hour after ICU admission)
Trial: 25844160
Drug: 12-week PATCH
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week PATCH intervention + usual care
Trial: 25846031
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal system (≤ 14 mg/24 h; dose adjustments ≤ 16 mg/24 h permitted)
Trial: 25846669
Drug: Intratumoral TG1042
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral TG1042 injection (adenovirus expressing IFN-γ) combined with tumor-infiltrating lymphocytes (TILs)
Trial: 25847227
Drug: Glass-based yttrium
RxNorm normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass-based yttrium 90 therapy
Trial: 25847929
Drug: Gemcitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m(2) IV on days 1 and 8), Carboplatin (AUC 2 IV on days 1 and 8), Iniparib (5.6 mg/kg IV on days 1, 4, 8, and 11) administered every 21 days for four cycles (amended to six cycles).
Trial: 25847936
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m(2) every 3 weeks)
Trial: 25848948
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous vitamin C (IVC) combined with chemotherapy
Trial: 25848948
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous vitamin C (IVC)
Trial: 25849571
Drug: Sequential Organ
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores
Trial: 25849721
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg three times daily for ≥2 weeks
Trial: 25852820
Drug: Adjuvant Adriamycin-based
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant Adriamycin-based chemotherapy with increased BFI scores (32 patients)
Trial: 25852962
Drug: End-tidal CO2
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-tidal CO2 (EtCO2) monitoring using a dedicated naso-buccal sensor during non-invasive ventilation (NIV)
Trial: 25853747
Drug: Ibrutinib at
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib at a daily dose of 420 mg
Trial: 25855376
Drug: Prophylaxis (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis (recombinant FVIII-FS 20-30 IU/kg thrice weekly)
Trial: 25855621
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day, oral) until disease progression, intolerable toxicity or death
Trial: 25855621
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day, oral) in non-smokers with adenocarcinoma
Trial: 25855621
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day, oral)
Trial: 25856269
Drug: Catheter-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-directed therapy (CDT) with low-dose hourly infusion of tissue plasminogen activator (tPA) or urokinase; average doses were 28.0 ± 11 mg tPA (n = 76) and 2,697,101 ± 936,287 International Units for urokinase (n = 23).
Trial: 25856269
Drug: Catheter-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-directed therapy (CDT)
Trial: 25856546
Drug: botulinum toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: botulinum toxin-A (BoNT-A) treatment
Trial: 25858498
Drug: Cixutumumab 1
RxNorm normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab 1 mg/kg, 3 mg/kg, or 6 mg/kg intravenously on days 1/8/15 with doxorubicin 75 mg/m² as a 48 h infusion on day 1 of a 21 day cycle
Trial: 25858498
Drug: Cixutumumab alone
RxNorm normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab alone after six cycles of combination therapy
Trial: 25858546
Drug: Testosterone ablation
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone ablation therapy
Trial: 25858546
Drug: Estradiol replacement
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol replacement therapy
Trial: 25860203
Drug: Goal-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed therapy administered by a specialized pediatric transport team
Trial: 25861217
Drug: Treatment selected
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment selected to target a somatic mutation in the tumor
Trial: 25862507
Drug: Malaligned Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaligned Group (MG)
Trial: 25862716
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LASac and Systolic Blood Pressure
Trial: 25865468
Drug: Gliovac (ERC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliovac (ERC 1671) administered intradermally with human GM-CSF (Leukine(®)), preceded by low-dose cyclophosphamide regimen.
Trial: 25865468
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard of care treatment).
Trial: 25867467
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (44 μg subcutaneously three times weekly)
Trial: 25870087
Drug: AUY922 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUY922 (70 mg) and erlotinib (150 mg)
Trial: 25870087
Drug: AUY922 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUY922 and erlotinib (doses not specified for phase II)
Trial: 25870329
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) - 3 doses at 1-month intervals, 1 additional dose 6 months later, followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later
Trial: 25870329
Drug: 4-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-dose regimen of PCV13 followed by PPSV23
Trial: 25872574
Drug: Coloplast Titan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coloplast Titan IPP with NLMT and postoperative rehabilitation (daily inflation for 1 year)
Trial: 25872574
Drug: Postoperative rehabilitation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative rehabilitation (daily inflation for 1 year)
Trial: 25872787
Drug: Tafamidis 20
RxNorm normalized name: TAFAMIDIS 20MG TAB UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 20 mg daily
Trial: 25874001
Drug: AZD0530 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0530 50 mg
Trial: 25874001
Drug: AZD0530 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0530 100 mg
Trial: 25874001
Drug: AZD0530 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0530 125 mg
Trial: 25874991
Drug: TwHF extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF extract (10 mg three times daily for 12 months)
Trial: 25876473
Drug: Interferon β-1a
RxNorm normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon β-1a intramuscular 30μg
Trial: 25878729
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with fasting insulin (FINS)
Trial: 25878729
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with homeostasis model assessment of β-cell insulin secretion (HOMA-β)
Trial: 25879416
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal system (≤8 mg/24 h) as add-on to oral DA
Trial: 25879807
Drug: Diuretics (particularly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (particularly antialdosteronic diuretic agents)
Trial: 25879867
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of MVA
Trial: 25879867
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MVA (for vaccinia-experienced subjects)
Trial: 25880400
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg daily for 12 weeks (with optional increase to 120 mg after 8 weeks)
Trial: 25881847
Drug: Busulfan and
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan and fludarabine (Flu-BU) conditioning regimen after FLAG-IDA chemotherapy
Trial: 25882434
Drug: Renal angina
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal angina index (RAI) and biomarkers (NGAL, KIM-1, l-FABP, IL-18)
Trial: 25883641
Drug: Marine protein
RxNorm normalized name: Ascorbic Acid/Biotin/Coenzyme Q10/Grape Seed Extract/Hydrated Silica/Marine Protein/Mucopolysaccharides/Selenium/Vitamin A/Vitamin D/Vitamin E/Zinc 62 MG-50 MCG-5 MG-15 MG-60 MG-83 MCG-2417 IU-51 IU-25.5 IU-1.8 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine protein supplement (MPS)
Trial: 25883789
Drug: Oral salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral salt and water
Trial: 25883789
Drug: Intravenous isotonic
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous isotonic saline
Trial: 25884189
Drug: H1 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 DNA vaccine (4 mg intramuscularly with Biojector, 3 doses at 4-week intervals)
Trial: 25884189
Drug: H1 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 DNA vaccine
Trial: 25884515
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg administrated p.o. twice daily for 28-day treatment cycles
Trial: 25884515
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg administrated p.o. twice daily
Trial: 25885553
Drug: 5% Imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Imiquimod (IMQ) cream, applied once a day, 5 days per week, for 8-16 weeks
Trial: 25885553
Drug: 5% Imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Imiquimod (IMQ) cream for lesions >10 mm
Trial: 25885553
Drug: 5% Imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Imiquimod (IMQ) cream for lesions <10 mm
Trial: 25886021
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) dispersible formulation, 20 mg artemether/120 mg lumefantrine, given twice-daily for three days
Trial: 25886021
Drug: Three-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day regimen of AL dispersible formulation
Trial: 25886021
Drug: Dosing recommendations
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing recommendations for infants <5 kg
Trial: 25886603
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.03 ml)
Trial: 25886605
Drug: Panagen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panagen (5 mg, 6 tablets daily for 18 days during chemotherapy)
Trial: 25886605
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 tablets daily for 18 days during chemotherapy)
Trial: 25887027
Drug: Mean arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean arterial pressure titration from 65 mmHg to normal levels
Trial: 25887336
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 150 mg dose of fluconazole
Trial: 25887777
Drug: AFM13 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFM13 at doses of 0.01 to 7 mg/kg body weight
Trial: 25887777
Drug: AFM13 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFM13 at doses of ≥1.5 mg/kg
Trial: 25887777
Drug: AFM13 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AFM13 treatment
Trial: 25888272
Drug: ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ramucirumab 8 mg/kg on days 1 and 15 and paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle
Trial: 25888403
Drug: Closed-loop fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop fluid administration system
Trial: 25888646
Drug: PCV13 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (3 doses) followed by PPSV23 (1 dose)
Trial: 25888856
Drug: Couples' Health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples' Health CoOp intervention targeting men who use alcohol and other drugs and engage in unprotected sex, and their main female sex partners. The intervention includes components addressing substance use, sex risk, HIV and other STIs, gender roles, gender-based violence, communication skills, and goal-setting activities.
Trial: 25888961
Drug: Entropy in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entropy in the ophthalmic artery
Trial: 25889044
Drug: Pradigastat 20
RxNorm normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat 20 mg
Trial: 25889044
Drug: Pradigastat 40
RxNorm normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat 40 mg
Trial: 25889305
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (3 g/day for 6 weeks)
Trial: 25890322
Drug: Compliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance with nutritional supplements
Trial: 25891174
Drug: Pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (2 mg or 10 mg per kg every 3 weeks or 10 mg per kg every 2 weeks)
Trial: 25891993
Drug: C-FLAG (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-FLAG (fludarabine and cytarabine as a 24-hr continuous infusion without idarubicin)
Trial: 25892292
Drug: Serum magnesium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum magnesium (se Mg) deficiency group
Trial: 25892292
Drug: Serum magnesium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum magnesium (se Mg)
Trial: 25895428
Drug: Grazoprevir 100
RxNorm normalized name: grazoprevir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg and elbasvir 50 mg QD with weight-based ribavirin BID for 12 weeks